APPLICATION
NDA017469
TYPE
NDA
ORIGINAL APPROVAL
1973-07-10
LATEST ACTION
2024-12-18
ROUTE
OPHTHALMIC
DOSAGE FORM
SUSPENSION/DROPS
MARKETING STATUS
Prescription
Products
OMNIPRED · ReferencePrescription
PREDNISOLONE ACETATE 1% · SUSPENSION/DROPS · OPHTHALMIC
Approval history
2002-12-11Manufacturing (CMC) · Supplement 30 · standardAP
2002-12-04Manufacturing (CMC) · Supplement 29 · standardAP
2000-05-16Manufacturing (CMC) · Supplement 28 · standardAP
1999-08-17Manufacturing (CMC) · Supplement 27 · standardAP
1999-04-05Manufacturing (CMC) · Supplement 26 · standardAP
1999-03-09Manufacturing (CMC) · Supplement 25 · standardAP
1998-10-06Manufacturing (CMC) · Supplement 24 · standardAP
1998-08-04Manufacturing (CMC) · Supplement 23 · standardAP
1997-06-27Manufacturing (CMC) · Supplement 22 · standardAP
1996-03-18Manufacturing (CMC) · Supplement 21 · standardAP
1996-03-05Manufacturing (CMC) · Supplement 20 · standardAP
1995-11-01Manufacturing (CMC) · Supplement 19 · standardAP
1995-11-01Manufacturing (CMC) · Supplement 17 · standardAP
1995-08-29Efficacy · Supplement 18 · standardAP
1995-06-13Manufacturing (CMC) · Supplement 16 · standardAP
1991-08-22Labeling · Supplement 14AP
1991-04-10Manufacturing (CMC) · Supplement 15 · standardAP
1989-03-06Labeling · Supplement 11AP
1988-03-02Manufacturing (CMC) · Supplement 13 · standardAP
1986-03-12Manufacturing (CMC) · Supplement 12 · standardAP
1982-05-25Manufacturing (CMC) · Supplement 10 · standardAP
1979-05-24Manufacturing (CMC) · Supplement 8 · standardAP
1977-08-24Labeling · Supplement 7AP
1977-04-06Manufacturing (CMC) · Supplement 5 · standardAP
1977-04-06Manufacturing (CMC) · Supplement 3 · standardAP
1977-04-06Manufacturing (CMC) · Supplement 6 · standardAP
1977-04-06Manufacturing (CMC) · Supplement 4 · standardAP
1974-12-05Labeling · Supplement 1AP
1973-07-10Type 5 - New Formulation or New Manufacturer · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.